Why Illumina (ILMN) is a Top Growth Stock for the Long-Term

Core Viewpoint - Zacks Premium offers various tools and resources to help investors make informed decisions and enhance their confidence in stock market investments [1][2]. Group 1: Zacks Style Scores - Zacks Style Scores are complementary indicators that rate stocks based on value, growth, and momentum methodologies, aiding investors in selecting stocks likely to outperform the market in the short term [3]. - Each stock receives a rating from A to F based on its characteristics, with A being the highest score indicating a better chance of outperforming [4]. - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [4][5][6][7]. Group 2: Zacks Rank and Performance - The Zacks Rank is a proprietary stock-rating model that utilizes earnings estimate revisions to simplify portfolio building [8]. - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +23.86% since 1988, significantly outperforming the S&P 500 [9]. - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B, while also considering the direction of earnings estimate revisions [10][11]. Group 3: Company Spotlight - Illumina Inc. - Illumina Inc., based in San Diego, provides sequencing and array-based solutions for genetic and genomic analysis, serving various sectors including life sciences and oncology [12]. - The company holds a Zacks Rank of 3 (Hold) with a VGM Score of A, indicating potential for growth investors [13]. - Illumina is forecasted to achieve year-over-year earnings growth of 6.2% for the current fiscal year, with upward revisions in earnings estimates from analysts [13][14].